共 108 条
[1]
Frampton JE(2013)Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer Drugs 73 2031-2051
[2]
Cappuzzo F(2015)Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus Lung Cancer 87 89-95
[3]
Moro-Sibilot D(2014)First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2167-2177
[4]
Gautschi O(2012)Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 1011-1019
[5]
Boleti E(2011)Crizotinib in anaplastic large-cell lymphoma N Engl J Med 364 775-776
[6]
Felip E(2013)Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study Lancet Oncol 14 472-480
[7]
Groen HJ(2014)ALK-driven tumors and targeted therapy: focus on crizotinib Pharmacogenomics Pers Med 7 87-94
[8]
Germonpre P(2015)Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects J Clin Pharmacol 55 104-113
[9]
Meldgaard P(2015)Pharmacokinetics of crizotinib in NSCLC patients Expert Opin Drug Metab Toxicol 11 835-842
[10]
Arriola E(2007)Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol Cancer Ther 6 3314-3322